Nov 05, 2019
Amgen has announced to purchase 20.5% of the stake in Chinese-American drug company BeiGene. As per the deal signed, Amgen will develop and commercialize around two dozen of its on-market as well as experimental drug compounds for the treatment of cancer in China. The shares purchased are worth USD 2.7 bill...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper